Susan Jeffers

2.6k total citations · 2 hit papers
32 papers, 2.0k citations indexed

About

Susan Jeffers is a scholar working on Oncology, Surgery and Reproductive Medicine. According to data from OpenAlex, Susan Jeffers has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Surgery and 8 papers in Reproductive Medicine. Recurrent topics in Susan Jeffers's work include Cancer Treatment and Pharmacology (15 papers), Intraperitoneal and Appendiceal Malignancies (13 papers) and Ovarian cancer diagnosis and treatment (8 papers). Susan Jeffers is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Intraperitoneal and Appendiceal Malignancies (13 papers) and Ovarian cancer diagnosis and treatment (8 papers). Susan Jeffers collaborates with scholars based in United States and Israel. Susan Jeffers's co-authors include Franco M. Muggia, Susan Groshen, Alberto Gabizón, Beatrice Uziely, Tamar Safra, Denice Tsao‐Wei, Olga Lyass, Gerald J. Berry, Randal H. Henderson and Laila I. Muderspach and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Susan Jeffers

32 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 513 citations Franco M. Muggia, John D. Hainsworth et al. Journal of Clinical Oncology profile →
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

2000 505 citations Tamar Safra, Franco M. Muggia et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Susan Jeffers

Since Specialization

Citations

This map shows the geographic impact of Susan Jeffers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Jeffers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Jeffers more than expected).

Fields of papers citing papers by Susan Jeffers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Jeffers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Jeffers. The network helps show where Susan Jeffers may publish in the future.

Co-authorship network of co-authors of Susan Jeffers

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Jeffers. A scholar is included among the top collaborators of Susan Jeffers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Jeffers. Susan Jeffers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule 2005 ·Cancer Chemotherapy and Pharmacology ·Agustin A. García, Mahesh P. Pujari, Susan Jeffers, Syma Iqbal, Heinz‐Josef Lenz, Paul M. Beringer, Stan G. Louie	6
2	Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC) 2004 ·Investigational New Drugs ·Valerie K. Israel, Scott T. Tagawa, (unknown), Susan Jeffers, Derek Raghavan	8
3	Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2′-deoxyuridine and leucovorin 2001 ·Anti-Cancer Drugs ·Agustin A. García, Franco M. Muggia, Colin Paul Spears, Susan Jeffers, Howard Silberman, Mahesh P. Pujari, Robert T. Koda	4
4	Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers 2000 ·Gynecologic Oncology ·(unknown), (unknown), L Roman, Laila I. Muderspach, Alexander Burnett, Susan Jeffers, Franco M. Muggia	43
5	Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors. 1998 ·Journal of Clinical Oncology ·Agustin A. García, (unknown), (unknown), Michael S. Rogers, Susan Jeffers, Robert T. Koda, Franco M. Muggia	7
6	Phase I/II Study of Intraperitoneal Floxuridine and Platinums (Cisplatin and/or Carboplatin) 1997 ·Gynecologic Oncology ·Franco M. Muggia, Susan Jeffers, Laila I. Muderspach, Lynda D. Roman, (unknown), Susan Groshen, Tamar Safra, C. Paul Morrow	19
7	Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. breakdown → 1997 ·Journal of Clinical Oncology ·Franco M. Muggia, John D. Hainsworth, Susan Jeffers, Paul Miller, Susan Groshen, Matthew Tan, L Roman, Beatrice Uziely, Laila I. Muderspach, Agustin Garcia, Alexander Burnett, Filippo Greco, C. Paul Morrow, Linda J. Paradiso, (unknown)	513
8	Tolerance of paclitaxel 3-hour infusion with and without granulocyte colony-stimulating factor on a biweekly schedule. 1997 ·PubMed ·Agustin A. García, (unknown), Isaiah W. Dimery, Michael S. Rogers, Susan Jeffers, Franco M. Muggia	3
9	Abdomino-pelvic hypertherma and intraperitoneal carboplatin in epithelial ovarian cancer: Feasibility, tolerance and pharmacology 1996 ·International Journal of Radiation OncologyBiologyPhysics ·Silvia C. Formenti, Prakash N. Shrivastava, Michael D. Sapozink, Gabor Jozsef, Kenneth K. Chan, Susan Jeffers, (unknown), Franco M. Muggia	19
10	Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials 1996 ·Lung Cancer ·Franco M. Muggia, (unknown), Ronald B. Natale, Valerie K. Israel, (unknown), Amanda McRae, Michael S. Rogers, Susan Jeffers	24
11	A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer 1995 ·Cancer ·Leonard B. Saltz, Cynthia G. Leichman, Charles W. Young, Franco M. Muggia, John A. Conti, (unknown), Susan Jeffers, Lawrence P. Leichman	78
12	Intraperitoneal 5-fluoro-2?-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study 1995 ·Cancer Chemotherapy and Pharmacology ·Valerie K. Israel, (unknown), Franco M. Muggia, Anil Tulpule, Susan Jeffers, Lawrence Leichman, C. Paul Morrow, Lynda D. Roman, Cynthia G. Leichman, Kenneth K. Chan	21
13	Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. 1995 ·Journal of Clinical Oncology ·Beatrice Uziely, Susan Jeffers, Rut Isacson, (unknown), (unknown), Zohar Yehoshua, E Libson, Franco M. Muggia, Alberto Gabizón	386
14	Intraperitoneal 5-fluoro-2′-deoxyuridine with escalating doses of leucovorin: Pharmacology and clinical tolerance 1994 ·Investigational New Drugs ·Franco M. Muggia, Anil Tulpule, Anastassios D. Retzios, Fei Chen, Susan Jeffers, Cynthia G. Leichman, Lawrence Leichman, Colin Paul Spears, Kenneth K. Chan	5
15	Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome) 1994 ·Investigational New Drugs ·Perry P. Guaglianone, Kenneth K. Chan, (unknown), Rosemarie Hanisch, Susan Jeffers, (unknown), Franco M. Muggia	66
16	Intraperitoneal Carboplatin and Etoposide for Persistent Epithelial Ovarian Cancer: Analysis of Results by Prior Sensitivity to Platinum-Based Regimens 1993 ·Gynecologic Oncology ·Franco M. Muggia, Susan Groshen, Christy Russell, Susan Jeffers, Su‐Chiu Chen, John B. Schlaerth, John P. Curtin, C. Paul Morrow	16
17	Prolonged Continuous Infusion of Fluorouracil With Weekly Bolus Leucovorin: A Phase II Study in Patients With Disseminated Colorectal Cancer 1993 ·JNCI Journal of the National Cancer Institute ·Cynthia G. Leichman, Lawrence Leichman, Colin Paul Spears, (unknown), Susan Jeffers, Susan Groshen	47
18	Intraperitoneal therapy for ovarian cancer: Analysis of fluid distribution by computerized tomography 1992 ·Annals of Oncology ·Franco M. Muggia, (unknown), Susan Jeffers, Christy Russell, William D. Boswell, C. Paul Morrow, John P. Curtin, John B. Schlaerth	18
19	Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2′-deoxyuridine 1991 ·Cancer Chemotherapy and Pharmacology ·Franco M. Muggia, Kenneth K. Chan, Christy Russell, Nicoletta Colombo, James L. Speyer, (unknown), Susan Jeffers, Joan Sorich, Lawrence Leichman, Uziel Beller, (unknown)	20
20	Biological Modification of protracted infusion of 5-fluorouracil with weekly leucovorin 1990 ·Cancer Chemotherapy and Pharmacology ·Cynthia G. Leichman, Lawrence Leichman, Colin Paul Spears, Peter J. Rosen, Franco M. Muggia, Susan Jeffers, William Waugh	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact